Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xueyuantong Granules is a Traditional Chinese Medicine (TCM) botanical product developed by Jiangsu Jichuan Pharmaceutical Co., Ltd. It is primarily investigated for the treatment of patients in the convalescent stage of cerebral infarction (ischemic stroke). As a TCM formulation, it is designed to address the underlying pathology of stroke recovery, likely through mechanisms such as promoting blood circulation and resolving blood stasis. The drug has been evaluated in Phase II clinical trials in China to assess its safety and efficacy in improving neurological function and recovery outcomes in post-infarction patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xueyuantong Granules.